Gene · 974
Papers4,161
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
421 to 440 of 4,161
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Clinicopathologic and mutational profiles of primary breast diffuse large B cell lymphoma in a male patient: case report and literature review. | World J Surg Oncol | 2023 | 37884941 | PubTator, text mining | PubMed |
| Leveraging a disulfidptosis-related signature to predict the prognosis and immunotherapy effectiveness of cutaneous melanoma based on machine learning. | Mol Med | 2023 | 37884883 | PubTator, text mining | PubMed |
| A Specialized Epithelial Cell Type Regulating Mucosal Immunity and Driving Human Crohn's Disease. | bioRxiv | 2023 | 37873404 | PubTator, text mining | PubMed |
| A challenging diagnosis of plasmablastic lymphoma: importance of integrating morpholgy immunohistochemistry and flow cytometry findings (case report). | Pan Afr Med J | 2023 | 37869229 | PubTator, text mining | PubMed |
| The prognostic value of the tertiary lymphoid structure in gastrointestinal cancers. | Front Immunol | 2023 | 37868990 | PubTator, text mining | PubMed |
| Advances in Polatuzumab Vedotin-PIIQ Therapy: A Review of Treatment Efficacy in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma. | Pediatric Health Med Ther | 2023 | 37867604 | PubTator, text mining | PubMed |
| [Identification of Peripheral Blood GZMK + CD8 + T Cells As Biomarkers of Alzheimer's Disease Based on Single-Cell Transcriptome]. | Sichuan Da Xue Xue Bao Yi Xue Ban | 2023 | 37866940 | PubTator, text mining | PubMed |
| Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non-Asian patients with previously untreated diffuse large B-cell lymphoma in POLARIX. | Clin Transl Sci | 2023 | 37864313 | PubTator, text mining | PubMed |
| High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma. | Blood Adv | 2023 | 37862676 | PubTator, text mining | PubMed |
| miR-28-based combination therapy impairs aggressive B cell lymphoma growth by rewiring DNA replication. | Cell Death Dis | 2023 | 37852959 | PubTator, text mining | PubMed |
| Distinct molecular subtypes of systemic sclerosis and gene signature with diagnostic capability. | Front Immunol | 2023 | 37849750 | PubTator, text mining | PubMed |
| Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies. | Exp Hematol Oncol | 2023 | 37845755 | PubTator, text mining | PubMed |
| Single-cell RNA sequencing distinctly characterizes the wide heterogeneity in pediatric mixed phenotype acute leukemia. | Genome Med | 2023 | 37845689 | PubTator, text mining | PubMed |
| Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting. | Front Immunol | 2023 | 37841262 | PubTator, text mining | PubMed |
| Next-generation sequencing in dermatology. | Front Med (Lausanne) | 2023 | 37841001 | PubTator, text mining | PubMed |
| Extracellular Vesicles in Triple-Negative Breast Cancer: Immune Regulation, Biomarkers, and Immunotherapeutic Potential. | Cancers (Basel) | 2023 | 37835573 | PubTator, text mining | PubMed |
| Up-Front ASCT Overcomes the Survival Benefit Provided by HDAC-Based Induction Regimens in Mantle Cell Lymphoma: Data from a Real-Life and Long-Term Cohort. | Cancers (Basel) | 2023 | 37835453 | PubTator, text mining | PubMed |
| B Cell Tolerance and Targeted Therapies in SLE. | J Clin Med | 2023 | 37834911 | PubTator, text mining | PubMed |
| Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody. | Cells | 2023 | 37830579 | PubTator, text mining | PubMed |
| Divergent molecular events underlying initial T-cell commitment in human prenatal and postnatal thymus. | Front Immunol | 2023 | 37828991 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/974/papers?page=22